BioSpace News Archive

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for the second quarter ended June 30, 2021, after the US markets close on Monday, August 9, 2021.

Bridge Medicines and Cornell University announced an exclusive license agreement to develop UBR5 Inhibitors for the treatment of certain difficult-to-treat cancers such as triple-negative breast cancer.

Novian Health Inc., a clinical stage medical device company focused on the development of image-guided laser therapy for the focal destruction of malignant and benign breast tumors, announced the first closing of a private placement financing, raising total proceeds of over $5 million.

Galaxy Medical announced today that the ECLIPSE-AF 90-day remapping data, presented at the Stanford BioDesign New Arrhythmia Technologies retreat, demonstrated durable lesions and chronic pulmonary vein isolation (PVI).

AAD, developer of rapid diagnostic and data systems, announced Dr. Rob Readnour and Joe Cook, III, both of Mountain Group Partners, and James Herbert, founder and former CEO of Neogen, have joined the company’s board of directors.

THREAD, a technology and service provider enabling decentralized clinical trials (DCTs), and Almac Clinical Technologies, a member of the contract and development organization, Almac Group, today announced a strategic partnership.

Kriya Therapeutics, Inc., a fully integrated platform company pioneering novel technologies and therapeutics in gene therapy, today announced the completion of the renovation of its 51,000 square foot facility located in Research Triangle Park, North Carolina to support cGMP production of its expanding pipeline of gene therapies.

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to TAK-994,1 its Phase 2 investigational oral orexin agonist, which is designed to selectively target orexin 2 receptors.

NTT Research, Inc., a division of NTT (TYO:9432), today announced that it has entered a joint research agreement with The University of Tokyo’s International Research Center for Neurointelligence (IRCN) to develop Coherent Ising Machine (CIM)-related technologies.

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced four new ready-to-use AlphaLISA® KRAS kits, designed to help scientists better understand complex KRAS protein structures and mutations so they can more easily, quickly, and precisely identify potential new therapeutic candidates for a wide range of prevalent cancers.